Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Potassium Pilot Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04251468
Recruitment Status : Completed
First Posted : February 5, 2020
Last Update Posted : September 16, 2020
Sponsor:
Collaborator:
NGFI Next Generation Fluorescence Imaging GmbH
Information provided by (Responsible Party):
Medical University of Graz

Brief Summary:
In this pilot study, 30 prevalent hemodialysis patients will undergo three regular hemodialysis sessions during which various potassium assessments will be performed. Pre- (t1) and post-dialysis (t2) plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes. These values will be correlated to K+ determine in saliva probes (K+Sa) using genetically encoded potassium ion indicators (GEPIIs). Additionally, continuous ECG will be recorded during each hemodialysis treatment and potassium assessment (K+ECG) will be performed upon ECG-based parameters and correlated to K+Pl.

Condition or disease Intervention/treatment Phase
Hyperkalemia Device: GEPII Device: Ion-selective electrodes Not Applicable

Detailed Description:

Cardiovascular diseases are among the leading causes of death in industrialized countries. Medical therapy for these diseases has seen significant progress, much of which is based on agents interfering with the renin-angiotensin-aldosterone system (angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, mineralocorticoid receptor antagonists, neprilysin inhibitors). However, these agents bear the side effect of reducing renal potassium (K+) excretion and may thus lead to elevation of blood K+ Levels (hyperkalemia). Hyperkalemia is a potentially life-threatening condition, which in its most severe forms requires immediate medical attention, since there is imminent danger of dangerous arrhythmias and sudden cardiac death. Therefore, hyperkalemia is a leading reason to withdraw potentially lifesaving therapy in a significant number of patients, which is considered to have a negative impact on patient outcomes. Recently, novel intestinal potassium binders have been shown to be efficient in reducing incidence and severity of hyperkalemia These compounds have very recently been shown to allow extending the benefits of antihypertensive therapy with spironolactone to patients with chronic kidney disease with refractory hypertension . Yet due to preanalytical problems as well as time and cost-restraints, out-patient monitoring of serum or plasma potassium levels has proven problematic.

The plasma potassium level and kinetics at two timepoints before and after a hemodialysis session as determined by either standard of care (i.e. ion selective electrode) will be compared to the potassium level measured in (i) saliva (salivary potassium [K+Sa]) or (ii) determined based on electrocardiogram (K+ECG). Patients suffering from end-stage renal disease undergoing hemodialysis (HD) frequently present with severe hyperkalemia prior to a HD session. During HD treatment, K+ levels undergo unphysiologically rapid changes due to K+ removal via HD as well as due to changes in acid-base status. Thus, HD patients represent a unique population in whom significant K+ derangements and rapid K+ Level changes predictably occur and where these phenomena can be investigated in a safe environment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Clinical Potassium Pilot Study
Actual Study Start Date : April 29, 2020
Actual Primary Completion Date : September 9, 2020
Actual Study Completion Date : September 9, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Potassium

Arm Intervention/treatment
GEPII
All patients who completed the study.
Device: GEPII
Saliva probes (K+Sa) will be measured using genetically encoded potassium ion indicators (GEPIIs)

Device: Ion-selective electrodes
Plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes.




Primary Outcome Measures :
  1. Relative difference in change of K+Sa at t2 versus t1 [ Time Frame: Pre- (t1) and immediately post-dialysis (t2) ]
    Assess the performance of K+Sa compared to K+Pl

  2. ECG P wave height [ Time Frame: Pre- (t1) and immediately post-dialysis (t2) ]
    Comparison of the relative change of K+ECG at t2 versus t1

  3. ECG PR interval [ Time Frame: Pre- (t1) and immediately post-dialysis (t2) ]
    Comparison of the relative change of K+ECG at t2 versus t1

  4. ECG QRS duration [ Time Frame: Pre- (t1) and immediately post-dialysis (t2) ]
    Comparison of the relative change of K+ECG at t2 versus t1

  5. ECG maximum R wave height [ Time Frame: Pre- (t1) and immediately post-dialysis (t2) ]
    Comparison of the relative change of K+ECG at t2 versus t1

  6. ECG QT interval [ Time Frame: Pre- (t1) and immediately post-dialysis (t2) ]
    Comparison of the relative change of K+ECG at t2 versus t1

  7. ECG ST segment depression [ Time Frame: Pre- (t1) and immediately post-dialysis (t2) ]
    Comparison of the relative change of K+ECG at t2 versus t1

  8. ECG maximum T wave height [ Time Frame: Pre- (t1) and immediately post-dialysis (t2) ]
    Comparison of the relative change of K+ECG at t2 versus t1


Secondary Outcome Measures :
  1. Percentage of false positive measurements, i.e. percentage where severe hyperkalemia [K+>6.0 mmol/L] was detected by means of K+ECG, which was not present in K+Pl [ Time Frame: Pre- (t1) and immediately post-dialysis (t2) ]
    Assess the performance of K+ECG compared to K+Pl

  2. Percentage of false negative measurement, i.e. percentage where severe hyperkalemia [K+>6.0 mmol/L] was not detected by means of K+ECG, which was present in K+Pl [ Time Frame: Pre- (t1) and immediately post-dialysis (t2) ]
    Assess the performance of K+ECG compared to K+Pl

  3. Severe hyperkalemia [K+Pl ≥ 6.5 mmol/L] detection rate using K+ECG: comparison of automated detection using the K+ECG algorithm vs experienced electrophysiologist. [ Time Frame: Pre- (t1) and immediately post-dialysis (t2) ]
    Assess the performance of K+ECG algorithm vs experienced electrophysiologist.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 to 90 years of age
  • End stage-renal disease or acute kidney injury patient undergoing hemodialysis
  • Ability to provide oral and written informed consent
  • Ability and willingness to comply with study procedures
  • Willingness to not consume foods or drinks other than water during dialysis session

Exclusion Criteria:

  • Intraventricular conduction abnormalities (left- or right bundle branch block, trifascicular block) which interfere with K+ECG determination
  • Active inflammation or infection of the oral mucous membranes or dentition

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04251468


Locations
Layout table for location information
Austria
Medical University of Graz
Graz, Austria
Sponsors and Collaborators
Medical University of Graz
NGFI Next Generation Fluorescence Imaging GmbH
Investigators
Layout table for investigator information
Principal Investigator: Alexander H. Kirsch, MD Medical University of Graz
Principal Investigator: Andras T. Deak, MD Medical University of Graz
Layout table for additonal information
Responsible Party: Medical University of Graz
ClinicalTrials.gov Identifier: NCT04251468    
Other Study ID Numbers: CPPS
First Posted: February 5, 2020    Key Record Dates
Last Update Posted: September 16, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Medical University of Graz:
plasma potassium measurement
saliva potassium measurement
hemodialysis
fluorescence assay
ECG-based potassium estimation
Förster resonance energy transfer
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperkalemia
Water-Electrolyte Imbalance
Metabolic Diseases